Abstract:Question What are the prognostic implications of luminal and basal subtypes in metastatic castration-resistant prostate cancer?Findings In this cohort study including tissue samples from 634 patients with metastatic prostate cancer, distinct molecular patterns associated with luminal and basal subtypes were identified; in addition, enrichment of small cell/neuroendocrine prostate cancer samples were noted in the basal tumors. The subtypes were prognostic, and the patients with luminal subtypes preferentially benefited from androgen-signaling inhibitors.Meaning These findings suggest that patients with luminal tumors should be considered for androgen-signaling inhibitor therapy, and those with basal tumors could be considered for chemotherapeutic approaches given the similarity to small cell/neuroendocrine prostate cancer and the diminished benefit of androgen-signaling inhibitors; further investigation is warranted in prospective clinical trials.Importance Luminal and basal subtypes of primary prostate cancer have been shown to be molecularly distinct and clinically important in predicting response to therapy. These subtypes have not been described in metastatic prostate cancer.Objectives To identify clinical and molecular correlates of luminal and basal subtypes in metastatic castration-resistant prostate cancer (mCRPC) and investigate differences in survival, particularly after treatment with androgen-signaling inhibitors (ASIs).Design, Setting, and Participants In this cohort study, a retrospective analysis was conducted of 4 cohorts with mCRPC (N = 634) across multiple academic centers. Treatment was at the physicians' discretion. Details of the study cohorts have been published elsewhere between 2016 and 2019. Data were analyzed from March 2018 to February 2021.Main Outcomes and Measures The primary clinical end point was overall survival from the date of tissue biopsy/molecular profiling. Luminal and basal subtypes were also stratified by postbiopsy ASI treatment. The primary molecular analyses included associations with small cell/neuroendocrine prostate cancer (SCNC), molecular pathways, and DNA alterations.Results In the 634 patients, 288 (45%) had tumors classified as luminal, and 346 (55%) had tumors classified as basal. However, 53 of 59 (90%) SCNC tumors were basal (P < .001). Similar to primary prostate cancer, luminal tumors exhibited overexpression of AR pathway genes. In basal tumors, a significantly higher rate of RB1 loss (23% basal vs 4% luminal; P < .001), FOXA1 alterations (36% basal vs 27% luminal; P = .03) and MYC alterations (73% basal vs 56% luminal; P < .001) were identified. Patients with basal tumors had worse overall survival compared with those with luminal tumors only in patients treated with an ASI postbiopsy (East Coast Dream Team: hazard ratio [HR], 0.39; 95% CI, 0.20-0.74; P = .004; West Coast Dream Team: HR, 0.57; 95% CI, 0.33-0.97; P = .04). Among patients with luminal tumors, those treated with an ASI had significantly better survival (HR, 0.27; 95% CI, 0.14-0.53; P < .001), whereas patients with basal tumors did not (HR, 0.62; 95% CI, 0.36-1.04, P = .07). The interaction term between subtype and ASI treatment was statistically significant (HR, 0.42; 95% CI, 0.20-0.89; P = .02).Conclusions and Relevance These findings represent the largest integrated clinical, transcriptomic, and genomic analysis of mCRPC samples to date, and suggest that mCRPC can be classified as luminal and basal tumors. Analogous to primary prostate cancer, these data suggest that the benefit of ASI treatment is more pronounced in luminal tumors and support the use of ASIs in this population. In the basal tumors, a chemotherapeutic approach could be considered in some patients given the similarity to SCNC and the diminished benefit of ASI therapy. Further validation in prospective clinical trials is warranted.

Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer

Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells

Abstract 476: Defining Two Populations of Prostate Cancer Cells with Distinct Molecular, Biological, and Tumor-Propagating Properties

The Transcriptomic Landscape of Prostate Cancer Development and Progression: an Integrative Analysis.

Identification of molecular subtypes and a prognostic signature based on chromatin regulators related genes in prostate cancer

Molecular Characterization of Clinically Defined Aggressive Variant Prostate Cancer (avpca) in Prospectively Collected Tissues and Corresponding Patient Derived Xenografts (PDX).

AVPC Molecular Signature Supplementary Figures from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes

Gene Expression Profiling Identifies Clinically Relevant Subtypes Of Prostate Cancer

Data from Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis

Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer

Single‐Cell RNA‐seq Reveals a Developmental Hierarchy Super‐Imposed Over Subclonal Evolution in the Cellular Ecosystem of Prostate Cancer

Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.

Insights into immune microenvironment and therapeutic targeting in androgen-associated prostate cancer subtypes

Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies

Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy

Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics

Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance

Identification of Molecular Markers Associated with Prostate Cancer Subtypes: An Integrative Bioinformatics Approach

Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer

Prostate Cancer Progression Modeling Provides Insight into Dynamic Molecular Changes Associated with Progressive Disease States